Comorbidities in DLBCL: too "Severe4" CAR-T therapy?

por Qualls, David, Jacobson, Caron A.
Publicado 2023

HIV-Associated Hodgkin's Lymphoma: Prognosis and Therapy in the Era of cART

por Jacobson, Caron A., Abramson, Jeremy S.
Publicado 2012

Does gender matter? Exploring mental health recovery court legal and health outcomes

por Kothari, Catherine L, Butkiewicz, Robert, Williams, Emily R, Jacobson, Caron, Morse, Diane S, Cerulli, Catherine
Publicado 2014

Salvage radiotherapy in relapsed/refractory large B-cell lymphoma after failure of CAR T-cell therapy

por Ababneh, Hazim S., Ng, Andrea K., Frigault, Matthew J., Abramson, Jeremy S., Johnson, Patrick Connor, Jacobson, Caron A., Patel, Chirayu G.
Publicado 2023

A phase 2 trial of defibrotide for the prevention of chimeric antigen receptor T-cell–associated neurotoxicity syndrome

por Jacobson, Caron A., Rosenthal, Allison C., Arnason, Jon, Agarwal, Shirali, Zhang, Peixin, Wu, Wendy, Amber, Vian, Yared, Jean A.
Publicado 2023

Low incidence of invasive fungal disease following CD19 chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma

por Little, Jessica S., Aleissa, Muneerah M., Beluch, Katherine, Gonzalez-Bocco, Isabel H., Marty, Francisco M., Manne-Goehler, Jennifer, Koo, Sophia, Hammond, Sarah P., Jacobson, Caron A.
Publicado 2022

Association of bridging therapy utilization with clinical outcomes in patients receiving chimeric antigen receptor (CAR) T-cell therapy

por Johnson, P Connor, Jacobson, Caron, Yi, Alisha, Gaballa, Mahmoud R, Horick, Nora, Rabideau, Dustin J, Lindell, Kevin, DePinho, Gabriel D, El-Jawahri, Areej R, Frigault, Matthew J
Publicado 2022

S223: REAL-WORLD EARLY OUTCOMES OF AXICABTAGENE CILOLEUCEL FOR RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

por Jacobson, Caron, Hemmer, Michael T., Hu, Zhen-Huan, Frank, Matthew, Popplewell, Leslie, Ahmed, Nausheen, Lin, Yi, Best, Timothy, Beygi, Sara, Miao, Harry, Fu, Christine, Sun, Fang, Xu, Hairong, Pasquini, Marcelo
Publicado 2023

Impact of COVID-19 Pandemic on Hematopoietic Stem Cell Transplantation (HSCT) and Immune Effector Cell (IEC) Therapies: A Large US Cancer Center Experience

por Maurer, Katie, Saucier, Anna, Kim, Haesook, Acharya, Utkarsh H., Mo, Clifton, Porter, Julie, Albert, Cindy, Wu, Catherine J., Soiffer, Robert, Cutler, Corey, Nikiforow, Sarah, Jacobson, Caron A., Ho, Vincent T.
Publicado 2021

Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma

por Miller, Kevin Charles, Johnson, Patrick Connor, Abramson, Jeremy S., Soumerai, Jacob D., Yee, Andrew J., Branagan, Andrew R., O’Donnell, Elizabeth K., Saucier, Anna, Jacobson, Caron A., Frigault, Matthew J., Raje, Noopur S.
Publicado 2022

P1134: BISPECIFIC ANTI-CD20/19 CAR-T – ZAMTOCABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY DLBCL – INTERIM ANALYSIS RESULTS OF DALY-II-USA STUDY

por Shah, Nirav, Maziarz, Richard, Jacobson, Caron, Isufi, Iris, Ghosh, Monalisa, Ulrickson, Matthew, Perales, Miguel-Angel, Lunning, Matthew, Hardy, Nancy, Wijatyk, Anna, Ancukiewicz, Marek, Nallewar, Madhavi, Coleman, Kimberly, Prudner, Bethany, Eromosele, Esther, Kaleta, Remigiusz, Miklos, David
Publicado 2023

Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Immunogenicity among Chimeric Antigen Receptor T Cell Therapy Recipients

por Aleissa, Muneerah M., Little, Jessica S., Davey, Sonya, Saucier, Anna, Zhou, Guohai, Gonzalez-Bocco, Isabel H., Crombie, Jennifer L., Looka, Andrew, Baden, Lindsey R., Issa, Nicolas C., Hammond, Sarah P., Jacobson, Caron A., Sherman, Amy C.
Publicado 2023

Prognostic value of early positron emission tomography in patients with large B-cell lymphoma treated with anti-CD19 chimeric antigen receptor T-cell therapy

por Crombie, Jennifer L., Jacobson, Caron A., Redd, Robert, Shouse, Geoffrey, Herrera, Alex F., Chow, Victor A., Gauthier, Jordan, Mullane, Erin, Cahill, Kirk, Kline, Justin, Romancik, Jason, Cohen, Jonathon B., Saucier, Anna, Houot, Roch, Armand, Philippe, Hess, Brian
Publicado 2023

Forecasting immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor t-cell therapy

por Amidi, Yalda, Eckhardt, Christine A, Quadri, Syed A, Malik, Preeti, Firme, Marcos Santana, Jones, Daniel K, Jain, Aayushee, Danish, Husain H, Rubin, Daniel B, Jacobson, Caron A, Cash, Sydney S, Lee, Jong Woo, Dietrich, Jorg, Westover, M Brandon
Publicado 2022

Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11

por Jain, Michael D., Miklos, David B., Jacobson, Caron A., Timmerman, John M., Sun, Jennifer, Nater, Jenny, Fang, Xiang, Patel, Ankit, Davis, Madison, Heeke, Darren, Trinh, Tan, Mattie, Mike, Neumann, Frank, Kim, Jenny J., To, Christina, Filosto, Simone, Reshef, Ran
Publicado 2023

COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience

por Maurer, Katie, Saucier, Anna, Kim, Haesook T., Acharya, Utkarsh, Mo, Clifton C., Porter, Julie, Albert, Cindy, Cutler, Corey, Antin, Joseph H., Koreth, John, Gooptu, Mahasweta, Romee, Rizwan, Wu, Catherine J., Soiffer, Robert J., Nikiforow, Sarah, Jacobson, Caron, Ho, Vincent T.
Publicado 2021

Urelumab alone or in combination with rituximab in patients with relapsed or refractory B‐cell lymphoma

por Timmerman, John, Herbaux, Charles, Ribrag, Vincent, Zelenetz, Andrew D., Houot, Roch, Neelapu, Sattva S., Logan, Theodore, Lossos, Izidore S., Urba, Walter, Salles, Gilles, Ramchandren, Radhakrishnan, Jacobson, Caron, Godwin, John, Carpio, Cecilia, Lathers, Deanne, Liu, Yali, Neely, Jaclyn, Suryawanshi, Satyendra, Koguchi, Yoshinobu, Levy, Ronald
Publicado 2020

P1107: ZUMA-22: A PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD-OF-CARE THERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

por Flinn, Ian W., Jacobson, Caron, Nastoupil, Loretta J., Morschhauser, Franck, Davies, Andrew J., Buske, Christian, Corradini, Paolo, Lopez-Guillermo, Armando, Reshef, Ran, Parameswaran, Vinod, Sehgal, Alison, Tees, Michael, Lui, Christine, Xue, Wei, Beygi, Sara, Grechko, Nikolay, Bolsue, Pisita, Giovanetti, Alessandro, To, Christina, Nahas, Myrna
Publicado 2023

Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma

por Ghione, Paola, Palomba, M. Lia, Patel, Anik R., Bobillo, Sabela, Deighton, Kevin, Jacobson, Caron A., Nahas, Myrna, Hatswell, Anthony J., Jung, A. Scott, Kanters, Steve, Snider, Julia Thornton, Neelapu, Sattva S., Ribeiro, Maria Teresa, Brookhart, M. Alan, Ghesquieres, Herve, Radford, John, Gribben, John G.
Publicado 2022

PB2319: ZUMA-23: A GLOBAL, PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD OF CARE AS FIRST-LINE THERAPY IN PATIENTS WITH HIGH-RISK LARGE B-CELL LYM...

por Westin, Jason, Jacobson, Caron, Chavez, Julio C, Sureda, Anna, Morschhauser, Franck, Glass, Bertram, Dickinson, Michael, Davies, Andrew J., Flinn, Ian W., Maloney, David, Chamuleau, Martine, Tees, Michael, Xue, Allen, Shahani, Shilpa, Nikolajeva, Olga, Kang, Janet, Kaplan, Aida, Schupp, Marco, Miao, Harry, Rich, Elizabeth Shima
Publicado 2023